Development of a shared decision-making tool in vitiligo: an international study.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
10 2021
Historique:
accepted: 02 04 2021
pubmed: 9 4 2021
medline: 7 1 2022
entrez: 8 4 2021
Statut: ppublish

Résumé

Shared decision-making tools (SDMt) are visual tools developed to promote joint medical decisions between physicians and patients. There is a paucity of such tools in dermatology. To develop and validate a SDMt for use in specialized consultation for vitiligo. A prospective cross-sectional study was carried out from March 2019 to March 2020. We first conducted a qualitative study of topics discussed by patients and clinicians during therapeutic decision-making in the setting of a specialized consultation for vitiligo using an anchored-theory method, which allowed conceptualization of the SDMt. The usefulness of the SDMt was evaluated by a working group of multidisciplinary health workers and patients with vitiligo. Consensus on the final tool was obtained through an e-Delphi method. We recruited 30 patients with vitiligo for the qualitative study, which identified 91 topics related to therapeutic decision-making. Hierarchical clustering analysis confirmed the distribution of these topics in two subgroups (general treatment goals and priorities, and topics specific to each treatment). The consensus of a multidisciplinary group was used to develop the SDMt. The tool was comprised of eight A5 cards, which addressed face repigmentation; body repigmentation (limited area); body repigmentation (extended area); partial or complete depigmentation; coping with the disease; stabilization of disease; maintaining repigmentation; and disease information. Cognitive interviews confirmed the satisfaction, readability and usefulness of the SDMt. The SDMt was then translated and culturally validated in English. We developed a tool for shared decision-making in nonsegmental vitiligo, which we translated and cross-culturally validated in a US patient population with vitiligo to ensure its generalizability.

Sections du résumé

BACKGROUND
Shared decision-making tools (SDMt) are visual tools developed to promote joint medical decisions between physicians and patients. There is a paucity of such tools in dermatology.
OBJECTIVES
To develop and validate a SDMt for use in specialized consultation for vitiligo.
METHODS
A prospective cross-sectional study was carried out from March 2019 to March 2020. We first conducted a qualitative study of topics discussed by patients and clinicians during therapeutic decision-making in the setting of a specialized consultation for vitiligo using an anchored-theory method, which allowed conceptualization of the SDMt. The usefulness of the SDMt was evaluated by a working group of multidisciplinary health workers and patients with vitiligo. Consensus on the final tool was obtained through an e-Delphi method.
RESULTS
We recruited 30 patients with vitiligo for the qualitative study, which identified 91 topics related to therapeutic decision-making. Hierarchical clustering analysis confirmed the distribution of these topics in two subgroups (general treatment goals and priorities, and topics specific to each treatment). The consensus of a multidisciplinary group was used to develop the SDMt. The tool was comprised of eight A5 cards, which addressed face repigmentation; body repigmentation (limited area); body repigmentation (extended area); partial or complete depigmentation; coping with the disease; stabilization of disease; maintaining repigmentation; and disease information. Cognitive interviews confirmed the satisfaction, readability and usefulness of the SDMt. The SDMt was then translated and culturally validated in English.
CONCLUSIONS
We developed a tool for shared decision-making in nonsegmental vitiligo, which we translated and cross-culturally validated in a US patient population with vitiligo to ensure its generalizability.

Identifiants

pubmed: 33830502
doi: 10.1111/bjd.20137
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

787-796

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2021 British Association of Dermatologists.

Références

Alkhateeb A, Fain PR, Thody A et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16:208-14.
Elbuluk N, Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin 2017; 35:117-28.
Ezzedine K, Whitton M, Pinart M. Interventions for vitiligo. JAMA 2016; 316:1708-9.
Taieb A, Alomar A, Böhm M et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 2013; 168:5-19.
Oiso N, Suzuki T, Wataya-kaneda M et al. Guidelines for the diagnosis and treatment of vitiligo in Japan. J Dermatol 2013; 40:344-54.
Gawkrodger DJ, Ormerod AD, Shaw L et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008; 159:1051-76.
Elwyn G. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ 2006; 333:417-20.
Wieringa TH, Rodriguez-Gutierrez R, Spencer-Bonilla G et al. Decision aids that facilitate elements of shared decision making in chronic illnesses: a systematic review. Syst Rev 2019; 8:121.
Mullan RJ, Montori VM, Shah ND et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 2009; 169:1560-8.
Stacey D, Bennett CL, Barry MJ et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011; 10:CD001431.
J.Askham AC. Where are the patients in décision-making about their own care? Available at: http://www.who.int/management/general/decisionmaking/WhereArePatientsinDecisionMaking.pdf (last accessed 29 April 2021).
Stiggelbout AM, Van der Weijden T, De Wit MPT et al. Shared decision making: really putting patients at the centre of healthcare. BMJ 2012; 344:e256.
Hargraves I, LeBlanc A, Shah ND, Montori VM. Shared decision making: the need for patient-clinician conversation, not just information. Health Aff (Millwood) 2016; 35:627-9.
Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 1997; 44:681-92.
Whitney SN. A new model of medical decisions: exploring the limits of shared decision making. Med Decis Mak 2003; 23:275-80.
McLellan C, O’Neil AI, Cameron M et al. Facilitating informed treatment decisions in acne: a pilot study of a patient decision aid. J Cutan Med Surg 2019; 23:117-8.
Tan J, Wolfe B. A patient decision aid for psoriasis based on current clinical practice guidelines. Arch Dermatol 2012; 148:718-23.
O’Neil AI, McLellan C, Cameron M et al. Putting the patient in patient-centred care: pilot testing an updated patient decision aid for plaque psoriasis. J Cutan Med Surg 2019; 23:119-20.
Tan J, Linos E, Sendelweck MA et al. Shared decision making and patient decision aids in dermatology. Br J Dermatol 2016; 175:1045-8.
Coulter A, Stilwell D, Kryworuchko J et al. A systematic development process for patient decision aids. BMC Med Inform Decis Mak 2013; 13(S2):S2.
Montori VM, Breslin M, Maleska M, Weymiller AJ. Creating a conversation: insights from the development of a decision aid. PLoS Medicine 2007; 4:e233.
Kaar SJ, Gobjila C, Butler E et al. Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid. BMC Psychiatry 2019; 19:309.
Coleman T. Using video-recorded consultations for research in primary care: advantages and limitations. Fam Pract 2000; 17:422-7.
Breslin M, Mullan RJ, Montori VM. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns 2008; 73:465-72.
Dew K. A health researcher’s guide to qualitative methodologies. Aust N Z J Public Health 2007; 31:433-7.
Starks H, Trinidad SB. Choose your method: a comparison of phenomenology, discourse analysis, and grounded theory. Qual Health Res 2007; 17:1372-80.
Lingard L, Albert M, Levinson W. Grounded theory, mixed methods, and action research. BMJ 2008; 337:a567.
Guest G, McLellan E. Distinguishing the trees from the forest: applying cluster analysis to thematic qualitative data. Field Methods 2003; 15:186.
Macia L. Using clustering as a tool: mixed methods in qualitative data analysis. Qual Rep 2015; 20:1083-94.
Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124:869-71.
van Geel N, Lommerts JE, Bekkenk MW et al. Development and validation of a patient-reported outcome measure in vitiligo: the Self Assessment Vitiligo Extent Score (SA-VES). J Am Acad Dermatol 2017; 76:464-71.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-6.
Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125:659-64.
van Beugen S, van Middendorp H, Ferwerda M et al. Predictors of perceived stigmatization in patients with psoriasis. Br J Dermatol 2017; 176:687-94.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606-13.
Hinz A, Klein AM, Brähler E et al. Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample. J Affect Disord 2017; 210:338-44.
Lavrakas PJ. Cognitive interviewing. Available at: http://methods.sagepub.com/reference/encyclopedia-of-survey-research-methods/n73.xml (last accessed 29 April 2021).
McCaffery KJ, Holmes-Rovner M, Smith SK et al. Addressing health literacy in patient decision aids. BMC Med Inform Decis Mak 2013; 13(S2):S10.
Contreras A, Garcia-Al R. The SOL formulas for converting SMOG readability scores between health education materials written in Spanish, English, and French. J Health Commun 1999; 4:21-9.
Gunning R. The Technique of Clear Writing. New York: Mcgraw-Hill, 1952.
Légaré F, Kearing S, Clay K et al. Are you SURE?: Assessing patient decisional conflict with a 4-item screening test. Can Fam Physician 2010; 56:e308-e314.
O’Connor AM. Validation of a decisional conflict scale. Med Decis Making 1995; 15:25-30.
Barr PJ, Thompson R, Walsh T et al. The psychometric properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decision-making process. J Med Internet Res 2014; 16:e2.
Vermeulen F, Kraaij G, Tupker R et al. Towards more shared decision making in dermatology: develop-ment of evidence-based decision cards for psoriasis and atopic eczema treatments. Acta Derm Venereol 2020; 100:adv00337.
Morrison T, Johnson J, Baghoomian W et al. Shared decision-making in dermatology: a scoping review. JAMA Dermatol 2021; 157:330-7.
Weymiller AJ, Montori VM, Jones LA et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med 2007; 167:1076-82.
Rodrigues M, Ezzedine K, Hamzavi I et al. Current and emerging treatments for vitiligo. J Am Acad Dermatol 2017; 77:17-29.

Auteurs

J Shourick (J)

Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), EA7379, Paris-Est University, UPEC, DHU VIC, Créteil, France.

M Ahmed (M)

Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.

J Seneschal (J)

Hôpital Saint-André, CHU Bordeaux, Bordeaux, France.

T Passeron (T)

Université Côte d'Azur, Department of Dermatology, CHU Nice, Nice, France.
Université Côte d'Azur, INSERM U1065, C3M, Nice, France.

N Andreux (N)

Hôpital Saint-André, CHU Bordeaux, Bordeaux, France.

A Qureshi (A)

Department of Dermatology, Warren Alpert Medical School, Brown University, 339 Eddy Street, Providence, RI, 02903, USA.

E Cho (E)

Department of Epidemiology, School of Public Health, Brown University, Providence, RI, 02903, USA.

P A Natella (PA)

Assistance Publique-Hôpitaux de Paris, Public Health Department/Clinical Research Unit (URC-Mondor), Groupe Hospitalier Henri-Mondor/Albert Chenevier, Créteil, France.

J Harris (J)

Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.

V-T Tran (VT)

Université de Paris, CRESS, INSERM, INRA, Paris, France.
Center d'Epidémiologie Clinique, Hôpital Hôtel Dieu, AP-HP, Paris, France.

K Ezzedine (K)

Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), EA7379, Paris-Est University, UPEC, DHU VIC, Créteil, France.
Department of Dermatology, Mondor Hospital (AP-HP), Paris Est Créteil University, Créteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH